1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Krka Keeps Up Strong Performance Despite Rouble Risks

The Company Remains Russia’s Largest Foreign Generics Provider

 
• By Adam Zamecnik

Krka has maintained strong growth in the past nine months despite ongoing questions surrounding its significant presence in Russia and foreign currency risks linked to the rouble.

(Shutterstock)

Krka has maintained its strong performance in 2024 as seen in its latest nine-month results despite slightly missing net profit consensus forecasts amid ongoing questions surrounding the company’s business in Russia and risks linked to the country’s currency.

Overall, Krka reported revenue of €1.43bn ($1.51bn) in the past nine months, which marked a 7% year-on-year increase. Alongside this,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Generics Bulletin

Zentiva Strikes Deal With Aboca To Expand CHC Offering

 
• By Tom Gallen

Czech Republic's Zentiva snaps up Aboca portfolio adding supplement brands marketed in European countries such France, Italy and Spain.

Will Amarin Finally Launch An Authorized Generic Version Of Vascepa?

 
• By Dean Rudge

As it offloads commercial rights to the brand in Europe, Amarin has for the umpteenth time teased the possibility of launching an authorized generic version of Vascepa in the US.

Bio-Thera And SteinCares Add Mega-Blockbuster Dupilumab To Latin America Alliance

 
• By Dean Rudge

Bio-Thera Solutions is back with its third agreement with Costa Rica-based SteinCares for the supply of a biosimilar in Latin America – this time for the Chinese firm’s proposed rival to Sanofi and Regeneron’s Dupixent (dupilumab)